Advertisement

Search Results

Advertisement



Your search for Krishnansu Tewari matches 10 pages

Showing 1 - 10


Philip J. DiSaia, MD, Former President, Society of Gynecologic Oncology, American Board of Obstetrics & Gynecology, Dies at 81

The grandson of Italian immigrants, Philip J. DiSaia was born on August 14, 1937, in Providence, Rhode Island. He earned his Bachelor’s in Science at Brown University and his MD at Tufts University. Upon the advice of his mentor in medical school, Dr. DiSaia obtained 2 years of general surgery...

Adding Bevacizumab to Chemotherapy in Advanced Cervical Cancer

As reported in The Lancet by Krishnansu S. Tewari, MD, of the University of California-Irvine Medical Center, and colleagues, the final overall survival results of the phase III Gynecologic Oncology Group 240 trial show continued benefit of the addition of bevacizumab (Avastin) to chemotherapy in...

gynecologic cancers

Final Overall Survival Results of GOG 240 Trial Adding Bevacizumab to Chemotherapy in Advanced Cervical Cancer

As reported in The Lancet by Tewari et al, the final overall survival results of the phase III Gynecologic Oncology Group (GOG) 240 trial show continued benefit of the addition of bevacizumab (Avastin) to chemotherapy in patients with metastatic, persistent, or recurrent cervical carcinoma. Study...

gynecologic cancers

Practice-changing Study Shows Survival Benefit for Antiangiogenesis in Advanced Cervical Cancer 

The addition of bevacizumab (Avastin) to chemotherapy prolongs overall survival in women with metastatic cervical cancer compared with chemotherapy alone, according to the results of a randomized phase III study presented at the Plenary Session of the ASCO Annual Meeting.1 Women on the...

gynecologic cancers

Timely Findings From the Ovarian Tumor Tissue Analysis Consortium 

In the Ovarian Tumor Tissue Analysis Consortium Study recently published by Sieh et al,1  tissue microarrays from 2,933 cases of epithelial ovarian carcinoma demonstrated that progesterone receptor (PR) expression and estrogen receptor (ER) expression were associated with significantly improved...

gynecologic cancers

Moore Scoring System Helps Identify Women With Advanced Cervical Cancer Who May Not Benefit From Bevacizumab

Previously published reports from the randomized phase III Gynecologic Oncology Group (GOG) protocol 240 clinical trial showed that adding bevacizumab (Avastin) to a chemotherapy regimen of paclitaxel plus cisplatin or topotecan significantly increased overall survival and progression-free survival ...

gynecologic cancers
gynecologic cancers

Experimental Immunotherapy Delays Recurrence for Stage III and IV Ovarian Cancers

According to a phase II study presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, an experimental immunotherapy is in the works that can target an individual woman’s ovarian tumor and extend the time period between initial treatment and the cancer’s...

gynecologic cancers

Adding Bevacizumab to Chemotherapy Improves Survival in Advanced Cervical Cancer

Retreatment with cisplatin has reduced effectiveness in patients with recurrent cervical cancer who have received cisplatin with radiation therapy. In a 2×2 factorial phase III trial reported in The New England Journal of Medicine, Tewari et al compared cisplatin/paclitaxel vs nonplatinum...

gynecologic cancers

ASCO 2013: Adding Bevacizumab to Chemotherapy Significantly Improves Response Rates and Survival in Women with Advanced Cervical Cancer

Adding bevacizumab (Avastin) to chemotherapy regimens with or without a platinum drug improved outcomes for women with metastatic or relapsed cervical cancer treated in a randomized phase III study. Presenting the results at the 2013 ASCO Annual Meeting (Abstract 3), lead author Krishnansu Sujata...

gynecologic cancers
gynecologic cancers

Bevacizumab Significantly Improves Survival for Patients with Recurrent and Metastatic Cervical Cancer

Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis of a large, randomized clinical trial. The...

Advertisement

Advertisement



;
Advertisement